anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Accurate radiation dose evaluation is important in patients with malignant tumors, and this is especially critical in children with NB who will be receiving several dose of therapeutic 131I. The accurate quantification of the isotope-labeled analog can only be achieved by using positron emission compounds, such as 124I. Unlike planar images, which were used to obtain kinetic information, and SPECT reconstruction modalities that were aimed to assess the spatial distribution of radioactivity, 3D PET imaging-based dosimetry is a method which provides a more accurate estimation of the cumulated radioactivity distribution. Because PET provides better quantitative accuracy, when compared to SPECT regarding the tissue absorbed information, we hypothesize PET would better correspond with tumor response and normal organ toxicity. Early studies using I-124 for dosimetry in thyroid cancer have been promising.

Demonstration of the feasibility and accuracy of this new imaging modality, with the excellent prospect for more accurate dosimetry, will improve tumor localization and optimize therapeutic dosing with 131I-MIBG. The results of our work may potentially have also implications in the study of other neuroendocrine tumors. The Section of Nuclear Medicine and the Laboratory of Functional Imaging at the University of California, San Francisco, are equipped with state of the art instruments and is run by a highly skilled staff which will guarantee the success of the proposed research.
PURPOSE:To provide the title compound of specific structure for use in e.g. anti-HIV agents which are also suitable for long-term administration due to low cytotoxicity and effective for preventing HIV infection and the prevention and therapy of AIDS. CONSTITUTION:A dideoxynucleotide (e.g. azidothymidine) is dissolved in tetrahydrofuran followed by addition, under ice chilling, of p-nitrophenyloxalyl chloride and triethylamine to make a reaction for 18hr, and the resulting reaction liquor is incorporated with L-prolyl-L-phenylalanine benzyl ester, etc., and 4-dimethylaminopyridine to make a reaction under agitation for 24hr. After completing the reaction, the system is concentrated under reduced pressures followed by washing and then, purification by silica gel chromatography, thus giving the objective compound of the formula [R<1> is H; R<2> is alkyl, hydroxymethyl, etc.; R<3> is (substituted) benzyl; X is lower alkoxy, etc.; Y is H or azido; B is nucleate group].
Participants of the repetitive-task practice group will complete repetitive practice of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each participant completed at least 20 repetitions of the task.
Rucaparib is an inhibitor of the mammalian polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme. The chemical name is 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic acid salt. The chemical formula of rucaparib camsylate is C 19H 18FN 3O•C 10H 16O 4S and the relative molecular mass is 555.67 Daltons. 

The chemical structure of rucaparib camsylate is shown below:

Rucaparib camsylate is a white to pale yellow powder; formulated into a tablet for oral use. Rucaparib shows pH-independent low solubility of approximately 1 mg/mL across the physiological pH range.

Rubraca (rucaparib) tablets contain rucaparib camsylate as the active ingredient. Each 200 mg tablet contains 344 mg rucaparib camsylate equivalent to 200 mg rucaparib free base. Each 250 mg tablet contains 430 mg rucaparib camsylate equivalent to 250 mg rucaparib free base. Each 300 mg tablet contains 516 mg rucaparib camsylate equivalent to 300 mg rucaparib free base.

The inactive ingredients in Rubraca tablets include: microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. The cosmetic blue film coating for 200 mg tablets, cosmetic white film coating for 250 mg tablets, and cosmetic yellow film coating for 300 mg tablets is Opadry II containing polyvinyl alcohol, titanium dioxide, polyethylene glycol/macrogol, and talc. The coating is colorized as blue using brilliant blue aluminum lake and indigo carmine aluminum lake, or yellow using yellow iron oxide.
A method for monitoring disease across agricultural areas of interest is provided comprising displaying at least one virtual zone corresponding to an agricultural geographic area of interest on a map in an application on a first device, and receiving an alert message when the first device is in proximity to a virtual zone. The at least one virtual zone is defined by at least one geofence. Each virtual zone is associated with a level of risk that indicates a likelihood of an outbreak of a disease detrimental to agriculture. Each virtual zone is configured to receive access notification information from each geofence when tracked devices enter an area defined by that geofence. The access information includes the level of risk associated with other virtual zones from which the tracked devices came. The alert message indicates if the first device should enter that virtual zone.
Enrolled patients receive a medical device which monitors gait quality and collects information about the patients health status. Possible changes of intervention (drug or physical therapy) within the observational phase (8 weeks) are initiated and prescribed by physicians as a result of routine care process or patient contact based on their (deteriorated) health status. With the chosen endpoints, changes of patients empowerment, gait quality and system usability by using a monitoring device are monitored.
LYRICA at doses of 150 to 600 mg/day has been shown to be effective as adjunctive therapy in the treatment of partial onset seizures in adults. Both the efficacy and adverse event profiles of LYRICA have been shown to be dose-related. Administer the total daily dose in two or three divided doses. In general, it is recommended that patients be started on a total daily dose no greater than 150 mg/day (75 mg two times a day, or 50 mg three times a day). Based on individual patient response and tolerability, the dose may be increased to a maximum dose of 600 mg/day.

Because LYRICA is eliminated primarily by renal excretion, adjust the dose in patients with reduced renal function [see Dosage and Administration (2.5)].

The effect of dose escalation rate on the tolerability of LYRICA has not been formally studied.

The efficacy of add-on LYRICA in patients taking gabapentin has not been evaluated in controlled trials. Consequently, dosing recommendations for the use of LYRICA with gabapentin cannot be offered.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to compounds of formula ^ , where each R1 and R2 is independently selected from hydrogen, methyl, ethyl, or R1 and R2 form four-, five- or six-member ring together with amide nitrogen, said ring optionally containing oxygen atom; X represents bromine or chlorine; as well as to their pharmaceutically acceptable salts and enantiomers of formula I compounds and their salts. Invention also relates to application of compound on any of i.i. 1-21, to pharmaceutical composition, as well as to selected from the group compounds. ^ EFFECT: obtaining novel biologically active compounds, possessing antagonistic activity with respect to receptor NK1/NK2/NK3. ^ 27 cl, 4 ex
PROBLEM TO BE SOLVED: To obtain a vasopermeable sthenia suppressing agent useful for the prevention and treatment of carebral edema, carebral hemorrhage, or the like, by including a dihydropyridine derivative having calcium antagonistic action. SOLUTION: The objective agent is produced by including a dihydropyridine derivative having calcium antagonistic action and expressed e.g. by the formula [A is a (substituted)aromatic ring; R1 is H, a (substituted)hydrocarbon group or a (substituted)amino; R2 is a (substituted)hydrocarbon group; R3 and R4 are each an acyl] (e.g. manidipine hydrochloride). The administration rate of the agent for e.g. an adult patient with cerebral edema (60 kg body-weight) is usually 0.1-20 mg/kg per dose and preferably about 1-3 doses a day. The agent is useful for the prevention or treatment of traumatic cerebrovascular disorder, cerebral hemorrhage (especially relapse), cerebral edema, migraine, or the like.  It is also useful for the treatment of various symptoms induced by the above diseases such as emotional disorder (depression, anxiety, sleep disturbance, or the like), intellectual disorder (amnesia, dementia, or the like), derangement (epilepsy, schizophrenia, or the like).
The present invention relates to a nutritive traditional Chinese medicine product with medicine and food purposes for preventing and treating dermatitis, and a preparation method thereof. The nutritive product is prepared from the official traditional Chinese medicine materials with medicine and food purposes, such as garter snake, angelica dahurica, mint, lily, gardenia, purslane, rice bean, sesame, etc., has the advantages of low production cost, no environment pollution, good mouth feel, small dosage and positive effect, is suitable for different people of different ages and is easily accepted by patients. The medicinal materials and the medicinal characteristics of the traditional Chinese medicine prescription simultaneously give consideration to the functional protection and coordination of hearts, lungs, spleens, kidneys, etc., and fully embody the whole conception and the advantages of traditional Chinese medicines. The nutritive product makes medicinal effects and functions more comprehensive, treats both sources and symptoms, and realizes the high bourn that the whole medicinal characteristics of traditional Chinese medicines tend to placidity and mutually raise medicinal effects. The nutritive product is suitable for any people and has wide service ranges because all medicinal materials have official medicine and food purposes, positive efficacy and no toxic or side effect. The nutritive product has simple and uniform medication varieties and functions and flexible and various prescriptions, is adapted to various patient conditions, appropriately selects medication, and widens the concrete content and the application range of identifying and curing the diseases with traditional Chinese medicines.
Patients will receive an intravitreal aflibercept injection the first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward. Patients with decreased radiation maculopathy by one grade or more will extend re-evaluation by two weeks. Patients with increased radiation maculopathy by one grade or more will have re-evaluation decreased by one week. Patients that show no maculopathy grade change will remain at the same re-evaluation interval.
PROBLEM TO BE SOLVED: To obtain a low-toxic therapeutic agent with slight side effect, capable of inhibiting skin drying through promoting sweat secretion, including a specific spirooxathiolanequinuclidine derivative as effective ingredient. SOLUTION: This therapeutic agent including, as effective ingredient, a spirooxathiolanequinuclidine derivative of the formula [R1 and R2 are each a (substituted) alkyl] or an acid addition salt thereof [pref. cis-2-methylspiro(1,3- oxathiolane-5,3')quinuclidine hydrochloric acid addition salt], is obtained. This agent can be administered either orally or parenterally in the form of capsules, tablets, etc., and for oral administration, it can also be administered in the form of a suspension, emulsion, or the like; wherein it is preferable to contain 1-95 wt.% of the compound of the formula. For parenteral administration as a local or perrectal preparation, it is preferable to contain 0.5-30 wt.% and 1-95 wt.% of the compound of the formula for ointments and suppositories, respectively. the dose of this therapeutic agent is appropriately 1 mg to 1 g per adult.
Medication is a potential factor influencing frailty. However, the relationship between pharmaceutical treatments and frailty remains unclear. Therefore, we conducted the present systematic review to summarize the association between drug therapy and the risk of incident frailty in older adults. We systematically searched the MEDLINE electronic database for articles indexed between January 1, 2000, and December 31, 2021, for randomized controlled trials (RCTs) and cohort studies reporting frailty changes associated with drug therapy. A total of six RCTs and 13 cohort studies involving 211,948 participants were identified, and their treatments were categorized into six medication classes: analgesics, cardiometabolic medication, chemotherapy, central nervous system (CNS)-active medication, hormonal therapy, and nutritional supplements. While the analysis revealed that only CNS-active medications were associated with an elevated risk of frailty, other medication classes also affected frailty; however, this is not conclusively attributable to a class-wide effect.
The inventors surprisingly found that neural stimulation caused the synthesis and degradation of proteins into peptides which were then secreted into the cell media within minutes of stimulation by a novel neural membrane bound proteasome (NMP). These secreted, activity-induced, proteasomal peptides (SNAPPs) range in size from about 500 Daltons to about 3000 Daltons. Surprisingly none of the peptides appear to be those previously known to have any neuronal function. Moreover, these SNAPPs have stimulatory activity and are heretofore a new class of signaling molecules. The present invention provides methods of modulating NMP function, including in cases of NMP associated disease or disorder of neuronal cells, by stimulating or inhibiting NMP function. The present invention also provides methods for stimulation or enhancing cognitive function using SNAPPs, and methods for treating of NMP related diseases using SNAPPs.
<P>PROBLEM TO BE SOLVED: To provide oral tablet formulations which overcome or improve issues (e.g. insolubility, instability and cracks of tablets) associated with oral conjugated estrogen tablets.  <P>SOLUTION: Oral conjugated estrogen formulations are disclosed and described. In one aspect, this oral formulation may be a tablet having a core and one or more coatings on this core. In addition to conjugated estrogen ingredients, this core may include one or more organic excipients and one or more inorganic excipients. In one aspect, this organic excipients may include less than about 20% (w/w) of a cellulose ingredient, and less than about 50% (w/w) of a sugar ingredient. In another aspect, this inorganic excipients may include less than about 10% (w/w) of a tricalcium phosphate ingredient. In yet another aspect, this formulation does not crack when stored at about 40°C and about 75% relative humidity for about 2 months.  <P>COPYRIGHT: (C)2011,JPO&INPIT
More than 619 million people in the world suffer from low back pain (LBP). As two potential inducers of LBP, intervertebral disc degeneration (IVDD) and fat infiltration of paraspinal muscles (PSMs) have attracted extensive attention in recent years. So far, only one review has been presented to summarize their relationship and relevant mechanisms. Nevertheless, it has several noticeable drawbacks, such as incomplete categorization and discussion, lack of practical proposals, etc. Consequently, this paper aims to systematically summarize and classify the interaction between IVDD and fat infiltration of PSMs, thus providing a one-stop search handbook for future studies. As a result, four mechanisms of IVDD leading to fat infiltration of PSMs and three mechanisms of fat infiltration in PSMs causing IVDD are thoroughly analyzed and summarized. The typical reseaches are tabulated and evaluated from four aspects, i.e., methods, conclusions, benefits, and drawbacks. We find that IVDD and fat infiltration of PSMs is a vicious cycle that can promote the occurrence and development of each other, ultimately leading to LBP and disability. Finally, eight perspectives are proposed for future in-depth research.
Levetiracetam in Sodium Chloride Injection is an antiepileptic drug available as a clear, colorless, sterile solution for intravenous administration. 

The chemical name of levetiracetam, a single enantiomer, is (-)-(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide, its molecular formula is C8H14N2O2 and its molecular weight is 170.21. Levetiracetam is chemically unrelated to existing antiepileptic drugs (AEDs). It has the following structural formula: 

Levetiracetam is a white to off-white crystalline powder with a faint odor and a bitter taste. It is very soluble in water (104.0 grams per 100 mL). It is freely soluble in chloroform (65.3 grams per 100 mL) and in methanol (53.6 grams per 100 mL), soluble in ethanol (16.5 grams per 100 mL), sparingly soluble in acetonitrile (5.7 grams per 100 mL) and practically insoluble in n-hexane. (Solubility limits are expressed as grams per 100 mL solvent.) 

Levetiracetam in Sodium Chloride Injection is a clear, colorless, sterile solution that is available in a single-dose dual port bag with an aluminum overwrap. The container closure is not made with natural rubber latex. 

500 mg per 100 mL: One 100 mL bag contains 500 mg of levetiracetam (5 mg per mL), water for injection, 820 mg sodium chloride, 5.5 mg of glacial acetic acid and buffered at approximately pH 5.5 with glacial acetic acid and 164 mg sodium acetate trihydrate. 

1,000 mg per 100 mL: One 100 mL bag contains 1,000 mg of levetiracetam (10 mg per mL), water for injection, 750 mg sodium chloride, 6.5 mg of glacial acetic acid and buffered at approximately pH 5.5 with glacial acetic acid and 164 mg sodium acetate trihydrate. 

1,500 mg per 100 mL: One 100 mL bag contains 1,500 mg of levetiracetam (15 mg per mL), water for injection, 540 mg sodium chloride, 7.5 mg of glacial acetic acid and buffered at approximately pH 5.5 with glacial acetic acid and 164 mg sodium acetate trihydrate.
Following the detection of severe hypoglycemia by the central nervous system (CNS), a series of physiological countermeasures are triggered which return serum glucose to euglycemic levels. This vital homeostatic response frequently becomes dysfunctional in both type 1 and type 2 diabetics, leaving them particularly vulnerable to life threatening bouts of hypoglycemia. This dysfunction, often termed hypoglycemia-associated autonomic failure (HAAF), is thought to be caused by maladaptive changes in the CNS. Currently, progress towards rectifying this HAAF is severely hindered by a lack of knowledge regarding the exact nature of these maladaptive changes and the antecedent events which cause them. Previous work by the PI, as well as others, has identified altered glial metabolism as a potential biological substrate driving HAAF. The alterations in glial metabolism associated with HAAF are strikingly similar to those induced by prolonged dietary restriction in rodents. This raises the intriguing possibility that HAAF may be driven by glial adaptations, normally induced only by prolonged starvation, which are triggered in diabetic individuals by treatment-induced exposure to severe hypoglycemia. The primary goal of our pilot project is to conduct a prospective observational study in humans to test the hypothesis that prolonged fasting will induce changes in glial metabolism similar to those previously measured in individuals with HAAF. The investigators will accomplish this goal via the following specific aims: Aim 1: Using a prospective observational study design in humans, test whether a 72 hour fast will induce acute alterations in glial metabolism, Aim 2: Determine if changes in plasma glucose and leptin levels following prolonged fasting are correlated with changes in glial adaptation. The investigators will utilize innovative 13C magnetic resonance spectroscopy to measure alterations in glial metabolism and substrate preference following acute dietary restriction in healthy young individuals. By demonstrating that metabolic adaptations of glial cells induced by prolonged fasting are similar to those previously associated with HAAF, the investigators can provide key insights into the precursors that may lead to the development of HAAF in diabetic individuals.
Standardized Cat Hair Extract may cause local or severe life-threatening reactions when administered to highly sensitive individuals. Physicians who use this product should be familiar with the clinical use of allergenic extract and have the necessary emergency equipment and medications available to treat systematic allergic reactions. See Precautions, Adverse Reactions and Overdosage.   
Standardized Cat Hair Extract should not be used interchangeably with Standardized Cat Pelt Extracts or previously standardized cat extracts labeled in Allergy Units per mL. Cat hair extracts labeled in BAU/mL made by other manufacturers should be tested for bioequivalency by serial titration skin testing before these products are used in patients who have previously received Allermed Standardized Cat Hair Extract.   
The dosage of Standardized Cat Hair Extract must be reduced when starting a patient on a new lot of Standardized Cat Hair Extract containing the same amount of Fel d 1 units per mL. This is necessary due to a possible loss of potency during storage in the physician's office. The dose of the new lot of extract should not exceed 1/4 the last dose given from the old lot of extract.   
Any evidence of a strong local reaction or systemic reaction following the administration of Standardized Cat Hair Extract requires a reduction in dosage during the initial stages of immunotherapy, as well as during maintenance therapy.
Thymomas are benign thymic epithelial neoplasms, rarely found outside the anterior mediastinum. Although hyperthyroid states have been associated with thymic hyperplasia, only 3 thymoma cases have been previously reported in patients with Graves disease (GD), all within the anterior mediastinum. Here, we report a case of ectopic cervical thymoma in a 22-year-old female patient previously treated for GD. The patient underwent ultrasonography, computed tomography, inconclusive fine-needle aspiration, and ultimately gross dissection for diagnostic workup and definitive treatment of an anterior neck mass, producing a 2.5 × 2.3 × 1.5-cm entity consistent with Masaoka stage I and type B2 thymoma per World Health Organization classification. The patient underwent an uncomplicated subsequent clinical course, with no adjuvant radiotherapy administered. After conducting a systematic literature review, we conclude that of the 109 cases of ectopic cervical thymoma reported, this is the first to describe a case of ectopic cervical thymoma in a patient with a past medical history of GD. For GD patients in stable euthyroid remission with the persistent or recurrent presence of an anterior neck mass, the extrathyroidal origin of the mass should always be considered, including the exceptional presence of a cervical ectopic thymoma.